Covaris Introduces the 96 oneTUBE-10 AFA Plate for Improved NGS Workflows

Food and Healthcare Press Releases Wednesday November 15, 2017 17:00
WOBURN, Massachusetts--15 Nov--PRNewswire/InfoQuest

Today, Covaris Inc. announced the release of the 96 oneTUBE-10 AFA Plate, which enables scalable and simplified workflows by leveraging Covaris' gold standard focused-acoustic technology to meet rapidly increasing Next-Generation Sequencing (NGS) demands for high-throughput and low-input library preparation.   By using the oneTUBE-10 offering, transfer steps within the NGS library prep workflow have been eliminated from mechanical DNA shearing (using Covaris' Adaptive Focused Acoustics(R) (AFA(R)) technology) through end repair, A-tailing, ligation, and SPRI clean-up.   The oneTUBE-10 product is specifically designed for use with Covaris' AFA technology for DNA shearing at volumes ranging from 10 to 50 Microliters, achieving highly accurate and reproducible results.

This new AFA vessel, is made of an engineered polymer for low impedance and efficient transmission of acoustic energy.   oneTUBE-10 effectively controls acoustic cavitation to enable reproducible and precisely-tuned hydrodynamic shear forces.   Designed to SLAS standards, oneTUBE-10 is compatible with standard heat blocks, magnets, and thermocyclers.   oneTUBE-10 can be used on any liquid handling platform, providing a universal solution for streamlining NGS workflows.   Paired with the LE220-plus (Covaris' newest Focused-ultrasonicator), NGS workflows are easily standardized by integration with high-throughput laboratory automation.

Covaris Founder and CEO, Jim Laugharn, said, "oneTUBE-10 is a game-changer for NGS workflows.   The combination of the Covaris AFA-energetics, the process behind the industry gold standard for robust, random, and unbiased DNA shearing, with a uniquely engineered polymer consumable enables highly automated library preparation, nucleic acid extraction, and additional applications in a single tube.   The improved workflow possibilities are unlimited!"

Future applications of oneTUBE-10 include FFPE extraction, enhanced ligation enzymatic reactions, and other biomolecular processes utilizing the Covaris technology.   AFA can now be applied at various steps including bead binding, mixing, and elution, while scaling down to low volumes.   Additionally, oneTUBE-10 product iterations will include an 8-strip format and will scale up to 384 well formats and beyond.

About Covaris, Inc.

Covaris is a recognized industry innovator in preanalytical sample preparation workflows involving sample stabilization, extraction, and processing.   Leveraging its patented Adaptive Focused Acoustics (AFA) technology and novel engineering solutions, Covaris has developed comprehensive packages of instrumentation, applications, reagents, and consumables to address the increasing sensitivity requirements of analytical technologies such as NGS and mass spectrometry.   Covaris Focused-ultrasonicators are recommended by all major NGS platform providers, and are used by leading Genome Centers worldwide.   The Covaris AFA process is extensively cited in peer-reviewed research articles on DNA fragmentation, ChIP, FFPE nucleic acid extraction, metabolomics, small molecule extraction, proteomics, and nanoemulsion formulation.   For more information, please visit: www.covaris.com .


Latest Press Release

Merck Signs Distribution Agreement with Avanti(R) Polar Lipids

Merck , a leading science and technology company, today announced that it has entered into an agreement with Avanti(R) Polar Lipids to be the exclusive multinational distributor of the USA-based company's research lipids portfolio outside of the United...

Xultophy(R) Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting

Newly published data from real-world European clinical practice has shown that Xultophy(R) (insulin degludec/liraglutide) significantly reduced blood sugar levels in people with type 2 diabetes after six months.[1] The study looked at people with type 2...

Tresiba(R) Reduces Hypoglycaemia Regardless of Blood Sugar Level

People with either type 1 or type 2 diabetes treated with Tresiba(R) had fewer episodes of low blood sugar (hypoglycaemia) compared with people on insulin glargine U100 regardless of whether they had achieved blood sugar targets.[1] These new post-hoc...

Ryzodeg(R) Significantly Reduces the Risk of Low Blood Sugar in People With Type 2 Diabetes who Fast During Ramadan

In people with type 2 diabetes who fast during Ramadan, Ryzodeg(R) (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe episodes by 62% and the rate of nocturnal hypoglycaemia by 74% versus...

Interim Results of First-Ever Global Survey Show People with Type 2 Diabetes Underestimate their Cardiovascular Risk

- Globally, cardiovascular disease (CVD) is the most common cause of death in people with type 2 diabetes[1] - 1 in 3 respondents considered themselves to be at low risk of CVD[2] - 1 in 6 respondents had never discussed type 2 diabetes and...

Related Topics